Therefore, to determine if CDKN2A mRNA expression could aid in prognostication for cases without any CDKN2A deletions, we dichotomized all CDKN2A intact meningiomas into 2 transcriptomic groups in each cohort based on their level of CDKN2A mRNA expression (Fig. 2a). Hereafter, we refer to these groups as CDKN2Ahigh and CDKN2Alow meningiomas. This evidence concerns the gene CDKN2A and meningioma.